Navigation Links
Broad-based group of physicians calls for improvement in stroke treatment
Date:8/20/2007

reatment, also known as endovascular stroke therapy, has been shown to be effective over a longer time period6 to 8 hours after the onset of stroke symptoms. Using this approach, a slender tube, or catheter, is threaded from an artery in the groin into the aorta, then up through the carotid arteries in the neck and into the specific artery in the brain that is blocked by a blood clot. In some cases, clot-busting medications are injected directly into the clot in hopes that it will dissolve. More often, a retrieval device with a corkscrew-like tip is passed through the catheter into the clot. When the device is pulled back into the catheter, it brings the clot with it. A stent is also sometimes implanted to prop open the artery.

Never before have we had the capability to manage this disease with such advanced techniques, said L. Nelson Hopkins, M.D., professor and chairman of neurosurgery and a professor of radiology at the State University of New York, Buffalo. We need to get that capability broadly disseminated so we can do a better job for stroke patients. Stroke is a disaster for patients, families, and society.

The ranks of those performing catheter-based treatment of stroke are alarmingly thin. There are only 385 interventional neuroradiologists practicing in the United States, according to survey data. In 5 states, not a single physician is available to perform endovascular stroke therapy.

The new document calls for solving this critical shortage by tapping into a group already trained in using catheters to treat carotid artery disease and strokes that occur as a complication of carotid stent placement, a procedure known as neuro-rescue. By adapting and expanding neuro-rescue skills, interventional cardiologists, interventional radiologists, and vascular surgeons could markedly increase the number of physicians available 24 hours a day, 7 days a week, to treat stroke.

This broad-based physician group would bring not only ex
'/>"/>

Contact: Kathy Boyd David
kbdavid@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. No link between blood groups and prostate cancer
2. Consumer group seeks Sibutramine ban
3. Suicide risk high in 12-17 Age Group
4. Religious groups overcome objections to cervical cancer vaccines
5. Wockhardt Group Plans Hospital In Delhi By End-2007
6. Group Suicides On The Rise In Japan
7. Yogic Moments: Age Old Yoga, Benefits All Age Groups
8. Group Jogging More Beneficial To Health Than Solo Jogging
9. Plastic Surgery Is Primetime among Ethnic Groups
10. Study Finds Online Support Groups Emotionally Benefit Women Suffering From
11. Specialist Services Can Help Ethnic Groups To Tackle Alcohol Misuse
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Within3 Expands into Mobile Applications 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 1Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 2Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 3Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 5Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 6URI research couples method targets cancerous tumors 60165 1URI research couples method targets cancerous tumors 60165 2URI research couples method targets cancerous tumors 60165 3URI research couples method targets cancerous tumors 60165 4Scientists are first to observe the global motions of an enzyme copying DNA 10548 1Scientists are first to observe the global motions of an enzyme copying DNA 10548 2Scientists are first to observe the global motions of an enzyme copying DNA 10548 3Scientists are first to observe the global motions of an enzyme copying DNA 10548 4